Koers Pain Therapeutics, Inc. Nasdaq
Aandelen
US69562K5065
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 300 mln. 281 mln. | Marktkapitalisatie | 966 mln. 904 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -92 mln. -86,04 mln. | Nettowinst (verlies) 2025 * | 120 mln. 112 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,22 x |
K/w-verhouding 2024 * |
-11,1
x | K/w-verhouding 2025 * |
13,4
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,82% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01-05-98 |
Eric Schoen
DFI | Director of Finance/CFO | 55 | 01-10-18 |
James Kupiec
CTO | Chief Tech/Sci/R&D Officer | - | 04-01-21 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Remi Barbier
CEO | Chief Executive Officer | 64 | 01-05-98 |
Robert Gussin
BRD | Director/Board Member | 86 | 01-03-03 |
Patrick Scannon
BRD | Director/Board Member | 76 | 07-12-07 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |